Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Colorcon
Healthtrust
Boehringer Ingelheim
Daiichi Sankyo
UBS
Farmers Insurance
Citi
Chinese Patent Office

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,216,167

« Back to Dashboard

Which drugs does patent 9,216,167 protect, and when does it expire?

Patent 9,216,167 protects ACULAR LS and is included in one NDA.

This patent has four patent family members in three countries.
Summary for Patent: 9,216,167
Title:Ketorolac tromethamine compositions for treating or preventing ocular pain
Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
Inventor(s): Muller; Christopher A. (Foothill Ranch, CA), Cheetham; Janet K. (Laguna Niguel, CA), Kuan; Teresa H. (Placentia, CA), Power; David F. (Trabuco Canyon, CA)
Assignee: Allergan Sales, LLC. (Irvine, CA)
Application Number:14/533,798
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,216,167

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan ACULAR LS ketorolac tromethamine SOLUTION/DROPS;OPHTHALMIC 021528-001 May 30, 2003 AT RX Yes Yes ➤ Subscribe ➤ Subscribe A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,216,167

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,648,107 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Subscribe
8,008,338 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Subscribe
8,207,215 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Subscribe
8,906,950 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Subscribe
8,541,463 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Subscribe
8,377,982 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Subscribe
8,946,281 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,216,167

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3217937 ➤ Subscribe
Canada 2967362 ➤ Subscribe
Canada 2468664 ➤ Subscribe
World Intellectual Property Organization (WIPO) 2016077726 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Julphar
Cerilliant
Covington
Novartis
Colorcon
Deloitte
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot